XML 13 R9.htm IDEA: XBRL DOCUMENT
v3.20.1

Intangible Asset | 3 Months Ended
--- | ---
Mar. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract] |
Intangible Asset |
(3) | Intangible Asset
Intangible asset consists of the historical acquisition cost of certain technology rights for Vascepa. Upon approval by FDA on December 13, 2019 of a new indication of Vascepa, a milestone for £5 million was achieved, which resulted in the Intangible asset increasing by $8.5 million. The Intangible asset has an estimated weighted-average remaining useful life of 10.3 years. The carrying value as of March 31, 2020 and December 31, 2019 is as follows:
In thousands |  | March 31, 2020 |  |  | December 31, 2019 |
Technology rights |  | $ | 20,081 |  |  | $ | 20,081 |
Accumulated amortization |  |  | (5,183 | ) |  |  | (4,823 | )
Intangible asset, net |  | $ | 14,898 |  |  | $ | 15,258 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration